In the past several years many laboratories have studied the significance of α and β tubulin proteins in antimicrotubule drug resistance. These studies have extended to several antimicrotubule agents in various carcinoma cell lines. Early studies showed mutations and alterations in the steady state soluble and polymerized α and β tubulin fractions in drug resistant cell lines Cabral et al, 1986; Minotti et al, 1991) . Although the existence of different α and β tubulin isotypes and their tissue specific expression was reported in the past, only recently demonstrated were the effects of individual β tubulin isotypes on overall microtubule functions including assembly, dynamics, drug sensitivity and drug binding. Banerjee et al (1990) have shown that β III isotype depleted tubulin assembles into microtubules at a faster rate than unfractioned tubulin. These microtubules are also more sensitive to paclitaxel-induced assembly compared to unfractioned tubulin (Lu and Luduena, 1993) . Subsequent studies revealed alterations in the expression of specific β tubulin isotypes as result of antimicrotubule drug resistance (Haber et al, 1995; Ranganathan et al, 1996; 1998a; 1998b; Kavallaris et al, 1997; Kavallaris et al, 1999) . In addition, combination studies have shown that cyclosporin A enhances paclitaxel efficacy in lung carcinoma cell lines by modulating β tubulin isotype composition (Ross and Antoniono, 1999) . Recently, Kavallaris et al, (1999) have shown that antisense oligonucleotides to β III isotype sensitized the drug resistant cells to paclitaxel. In addition, mutations in β I isotype were reported in paclitaxel resistant human ovarian carcinoma cells (Giannakakou et al, 1997) , breast carcinoma cells (Wiesen and Horwitz, 2000) and non-small-cell lung cancer patients (Monzo et al, 1999) with tumours that were unresponsive to paclitaxel therapy.
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Antimicrotubule drug resistance associated changes in tubulin isotypes prompted several investigators to determine the contribution of individual isotypes by transfecting cells and examining their antimicrotubule drug response. Wu et al (1998) have shown that transfection of β IVa isotype into human leukemic cell line failed to confer resistance to paclitaxel. Blade et al (1999) have over-expressed rodent β I , β II or β IVb isotypes in CHO cells and shown that these isotypes do not confer resistance to paclitaxel. Our previous work demonstrated increases in β III and β IVa isotypes in human prostate carcinoma cells that were made resistant to estramustine or paclitaxel (Ranganathan et al, 1996 (Ranganathan et al, , 1998a 
MATERIALS AND METHODS

Construction of expression vectors and selection of transfectants
Human β III cDNA that was previously cloned in our laboratory (Ranganathan et al, 1998b) and haemagglutinin antibodies (1:500, BabCo, Richmond, CA). Cells were stained with rhodamine-red-x conjugated antimouse secondary antibodies (1:800, Jacksonville Immunoresearch,) for 45 min at 37˚C, mounted onto slides, and examined. Images were captured with 12 bit cooled CCD (Quantix, Photometrics, Tuscon, AZ) and average pixel intensity values were quantitated and analysed by using Isee software (Inovision Corp., Raleigh/Durham, NC). At least 200 cells were quantited per each antibody stain and the average pixel intensities were calculated.
Western blot analysis of proteins from β III -transfectant and vector-transfectant cells
Cytosolic fractions were prepared from the cells and Western blots were analysed as described previously (Ranganathan et al, 1996) . Briefly, cells were lysed for 10 min at 4˚C in PBS containing 1% Triton X100, 0.1% SDS, 0.5% Sodium deoxycholate and protease inhibitors, followed by centrifugation at 10 000 × g for 10 min. Protein concentrations of the supernatants were estimated by the Biorad method (Hercules, CA). Proteins were fractionated by 8% polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Millipore, Bedford, MA). Western blots were probed with antibodies against HA epitope (1:500) and β III tubulin isotype (1:200) and developed using ECL plus chemiluminiscence detection system (Amersham Pharmacia Biotech, Piscataway, NJ). Results were quantitated by densitometric scanning of the films.
RT-PCR analysis of β tubulin isotype transcripts from pZeoSV and pZeoβ III -transfectant cells
RNA was isolated from both cell lines using RNAeasy kit from Qiagen Inc (Chadsworth, CA). β tubulin isotype-specific primers for the β I , β II , β III , β IVa and β IVb isotypes and the PCR conditions were described in detail previously (Ranganathan et al, 1996) . In addition, vector-specific and HA epitope specific primers were chosen using the primer detective program (Clontech, Palo Alto, CA) and synthesized by the DNA core facility at Fox Chase Cancer Center. PCR products were analysed by agarose gel electrophoresis and quantitated by densitometric scanning.
Cytotoxicity assays
ZeoSV and Zeoβ III transfectant cell lines were plated onto 96-well cell culture plates and allowed to attach. Estramustine was a gift from Kabi Pharmacia, Lund, Sweden (now Pharmacia, Bridgewater, NJ). Paclitaxel, vinblastine and colchicine were purchased from Sigma Chemical Co. Cells were exposed to various concentrations of the drugs for 48 h, fixed and stained with sulforhodamine B, as previously described (Ranganathan et al, 1996) . Absorbance was measured at 560 nm and cell survivals in both cell lines were determined.
RESULTS
Expression of β III tubulin isotype by transfection
When the cells were stained with antibodies against HA epitope, β III transfected cells showed significant staining for the HA epitope in the microtubules, indicating β III protein was derived from the pZeoβ III DNA and was incorporated into cellular microtubules ( Figure 1D ). By contrast, staining for the vector-transfected cells was similar to background level of staining ( Figure 1C ). When the cells were stained with the antibodies against β III isotype, a 2.4-fold increase in staining was seen in the β III transfectant cells ( Figure  1B ) compared to the vector transfected cells ( Figure 1A ). Cells were also stained with antibodies against pan α and pan β tubulin proteins to determine if the over-expression of β III isotype had any affect on the overall β and α tubulin levels ( Figure 1 E-H) . As shown in the figure, levels of β tubulin levels did not change significantly from vector-transfected cells ( Figure 1E ) to β III transfected cells ( Figure 1F ). There was a 1.8-fold increase of overall α tubulin levels in β III transfected cells ( Figure 1H ) compared to vector transfectant cells ( Figure 1G ). Quantiation of immunofluorescent staining was done as described in the Methods section and the results are shown in Table 1 . Western blot analysis of the proteins from the transfectant cell lines by use of HA antibodies has confirmed the increase seen by immunofluorescence (Figure 2) . Quantitation of the Western blot by NIH image analysis software revealed a 7-fold increase in the HA signal. There were no differences in the overall β tubulin and β tubulin levels between the vector transfected and β III transfected cell lines. RT-PCR analysis of RNA from the transfectant cells has shown that there was a significant increase of β III isotype mRNA, as seen by the elevation of overall β III levels and HA tagged β III levels.
( Figure 3A) . Quantitation of the image revealed a 3-fold increase of β III transcript levels compared to vector transfectants. There was a significant level of HA tagged β III transcript compared to no signal in the vector transfectants. β I and β IVa levels were similar in both cell lines. Interestingly, a collateral increase in the levels of β II and β IVb transcripts was seen in the β III transfected cells. The increases were quantified to be 7-fold and 2-fold for β II and β IVb transcripts, respectively. Immunofluorescent staining of the cells with corresponding antibodies has confirmed the increase at the protein level ( Figure 3B ).
Antimicrotubule drug response of transfectant cells
β III transfectant and vector control cell lines were treated with estramustine, paclitaxel, colchicine and vinblastine for 48 h, and dose response curves were determined (Figure 4 ). Cytotoxicity profiles of both cell lines were similar for each of the antimicrotubule agents tested, with IC50 values of 4 µM, 4nM and 2nM for estramustine, paclitaxel and vinblastine, respectively. For colchicine, the IC50 values were 15 and 17nM for β III transfected and vector transfected cells. Cell doubling times for β III transfectant and vector control cell lines were found to be very similar, ~22 h indicating that transfection of β III into cells did not alter cell cycle times.
DISCUSSION
Several in vitro studies have demonstrated that the β tubulin isotype composition of microtubules determines the differences in their functions including dynamics, assembly properties and sensitivity to antimicrotubule agents (Banerjee et al, 1990 Benerjee and Luduena, 1992; Luduena, 1993, 1994; Panda et al, 1994 Panda et al, , 1997 Derry et al, 1997) . Because antimicrotubule agents are widely used in cancer therapy, tubulin isotype composition of tumour cells may be an important factor in the success of therapy. Estramustine, vinblastine and paclitaxel have been shown to suppress microtubule dynamics at very low drug concentrations (Jordan et al, 1993 (Jordan et al, , 1996 Dhamodharan et al, 1995; Panda et al, 1997) . Work by Lu and Luduena (1993) demonstrated that microtubules lacking the β III isotype polymerized at a faster rate in the presence of paclitaxel than the microtubules from unfractioned tubulin. Derry et al (1997) have shown that suppression of microtubule dynamics by paclitaxel varies according to β tubulin isotype content, with αβ III microtubules and αβ IV microtubules being approximately 7-fold less sensitive to the drug than the microtubules from unfractionated tubulin. Work from many laboratories including our own has shown that cancer cell lines made resistant to antimicrotubule agents have altered tubulin isotype composition. In addition, Kavallaris et al (1999) have shown that antisense oligonucleotides to β III isotype sensitized paclitaxel resistant lung cancer cells to the drug. However, the data presented in this paper demonstrate that transfection and 3-fold over-expression of β III isotype in cells does not confer resistance to estramustine or paclitaxel. Increases of β tubulin isotypes seen in drug resistant cell lines might be due to the selection with antimicrotubule agents. Another reason for the lack of antimicrotubule drug resistance of β III transfectant cells might be the collateral increases of β II and β IVb levels. Cellular β tubulin levels are under autoregulation through cotranslational degradation of mRNAs (Theodorakis and Cleveland, 1992; Bachurski et al, 1994) . In addition, Gonzalez-Garay and Cabral (1995) have shown that over-expression of β I tubulin in Chinese hamster ovary cells resulted in coordinate increase of α tubulin levels. Based on the collateral increases of β II and β IVb levels in our β III transfectant cells, it is possible to conceive that cells compensate for overexpression of β III by autoregulation of these isotypes. Tubulin isotypes differ significantly from each other in their assembly properties (Lu and Luduena, 1994) . Microtubules from αβ II and αβ IV assembled much faster than unfractionated tubulin. αβ III dimers assembled at a very slow rate and had the highest critical concentration. However, in vitro analysis by Panda et al (1994) has shown that microtubules assembled from αβ III dimers were more dynamic than the microtubules from αβ II and αβ IV isotypes. They further demonstrated that addition of αβ II dimers to αβ III dimers suppressed microtubule dynamics. In addition, colchicine binding characteristics of αβ III dimers were significantly different from αβ II and αβ IV dimers, with apparant on-rate constants of 132 ± 5, 30 ± 2 and 236 ± 7 M -1 s -1 for αβ II , αβ III and αβ IV dimers, respectively . The data presented in this paper together with existing in vitro data support the hypothesis that cells might modulate their microtubule functions by altering tubulin isotype composition. The lack of antimicrotubule resistance seen in our β III transfectants, β IVa transfectants (Wu et al, 1999) and the rodent β I , β II or β IVb transfectants (Blade et al, 1999) altogether point to the conclusion that the β tubulin regulation is highly complex. When cells are transfected with an individual β tubulin isotype, cellular compensatory mechanisms come into play, including altered expression of endogenous β tubulin isotypes, which may alter the effects of the transfected isotype.
